PL360531A1 - Sposoby syntezy aplidyny, nowe przeciwnowotworowepochodne aplidyny oraz sposoby wytwarzania i użycia tych pochodnych - Google Patents

Sposoby syntezy aplidyny, nowe przeciwnowotworowepochodne aplidyny oraz sposoby wytwarzania i użycia tych pochodnych

Info

Publication number
PL360531A1
PL360531A1 PL36053101A PL36053101A PL360531A1 PL 360531 A1 PL360531 A1 PL 360531A1 PL 36053101 A PL36053101 A PL 36053101A PL 36053101 A PL36053101 A PL 36053101A PL 360531 A1 PL360531 A1 PL 360531A1
Authority
PL
Poland
Prior art keywords
methods
aplidine
making
new antitumoral
derivatives
Prior art date
Application number
PL36053101A
Other languages
English (en)
Other versions
PL208651B1 (pl
Inventor
Ignacio Rodriguez
Concepcion Polanco
Felix Cuevas
Paloma Mandez
Carmen Cuevas
Pilar Gallego
Simon Munt
Ignacio Manzanares
Original Assignee
Pharma Mar S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0016148A external-priority patent/GB0016148D0/en
Priority claimed from GB0103750A external-priority patent/GB0103750D0/en
Application filed by Pharma Mar S.A. filed Critical Pharma Mar S.A.
Publication of PL360531A1 publication Critical patent/PL360531A1/pl
Publication of PL208651B1 publication Critical patent/PL208651B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL360531A 2000-06-30 2001-07-02 Pochodne aplidyny o działaniu przeciwnowotworowym PL208651B1 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0016148A GB0016148D0 (en) 2000-06-30 2000-06-30 Synthetic methods for aplidine and new antitiumoral derivatives
GB0103750A GB0103750D0 (en) 2001-02-15 2001-02-15 Synthetic methods for aplidine and new antitumoral derivatives methods of making and using them
PCT/GB2001/002901 WO2002002596A2 (en) 2000-06-30 2001-07-02 Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them

Publications (2)

Publication Number Publication Date
PL360531A1 true PL360531A1 (pl) 2004-09-06
PL208651B1 PL208651B1 (pl) 2011-05-31

Family

ID=26244577

Family Applications (1)

Application Number Title Priority Date Filing Date
PL360531A PL208651B1 (pl) 2000-06-30 2001-07-02 Pochodne aplidyny o działaniu przeciwnowotworowym

Country Status (25)

Country Link
US (2) US7348310B2 (pl)
EP (1) EP1294747B1 (pl)
JP (1) JP5289662B2 (pl)
KR (1) KR100866056B1 (pl)
CN (2) CN104650177A (pl)
AT (1) ATE393775T1 (pl)
AU (1) AU6769801A (pl)
BR (1) BRPI0112375B8 (pl)
CA (1) CA2414609C (pl)
CY (1) CY1108549T1 (pl)
CZ (1) CZ304204B6 (pl)
DE (1) DE60133817T2 (pl)
DK (1) DK1294747T3 (pl)
ES (1) ES2305083T3 (pl)
HK (1) HK1052940B (pl)
HU (1) HU228998B1 (pl)
IL (2) IL153680A0 (pl)
MX (1) MXPA03000202A (pl)
NO (1) NO334096B1 (pl)
NZ (1) NZ523367A (pl)
PL (1) PL208651B1 (pl)
PT (1) PT1294747E (pl)
SI (1) SI1294747T1 (pl)
UA (1) UA76718C2 (pl)
WO (1) WO2002002596A2 (pl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030148933A1 (en) 1990-10-01 2003-08-07 Pharma Mar S.A. Derivatives of dehydrodidemnin B
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
IL149488A0 (en) * 1999-11-15 2002-11-10 Pharma Mar Sa Pharmaceutical compositions containing aplidine
ES2272462T3 (es) 2000-04-07 2007-05-01 The Trustees Of The University Of Pennsylvania Analogos de tamadarina y didemnina y procedimiento de fabricacion y uso.
US6509315B1 (en) 2000-04-07 2003-01-21 The Trustees Of The University Of Pennsylvania Didemnin analogs and fragments and methods of making and using them
UA76718C2 (uk) * 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
BR0114604A (pt) 2000-10-12 2003-10-14 Pharma Mar Sa Tratamento de c‰nceres
KR20060002778A (ko) 2003-03-12 2006-01-09 파르마 마르, 에스.에이. 개선된 항종양 치료
JP4584245B2 (ja) 2003-03-12 2010-11-17 ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド 多発性骨髄腫治療用のアプリジン
AU2004224418A1 (en) 2003-03-21 2004-10-07 Madeleine M. Joullie Tamandarin analogs and fragments thereof and methods of making and using
US20090226465A1 (en) * 2005-10-31 2009-09-10 Jackson David Y Macrocyclic depsipeptide antibody-drug conjugates and methods
HUE028055T2 (en) 2006-02-28 2016-11-28 Pharma Mar Sa Improved treatment of myeloma multiplex
AU2008313627A1 (en) * 2007-10-19 2009-04-23 Pharma Mar, S.A. Improved antitumoral treatments
CN101965191A (zh) * 2008-03-07 2011-02-02 法马马有限公司 改善的抗癌治疗
WO2011020913A2 (en) 2009-08-21 2011-02-24 Pharma Mar, S.A. Cyclodepsipeptide antiviral compounds
EP2614089A1 (fr) * 2010-09-10 2013-07-17 Sanofi-Aventis Polysaccharides biotinyles a activite antithrombotique et presentant une stabilite metabolique amelioree
LT3615544T (lt) 2017-04-27 2023-05-10 Pharma Mar S.A. Priešnavikiniai junginiai
CN115666616A (zh) 2020-03-02 2023-01-31 法马马有限公司 用于病毒感染的化合物
IL296067A (en) 2020-03-02 2022-11-01 Pharma Mar Sa Pld for use in combination in the treatment of coronavirus
US20230158104A1 (en) 2020-03-02 2023-05-25 Pharma Mar, S.A. Compounds for use in autoimmune conditions
EP4114436A1 (en) 2020-03-02 2023-01-11 Pharma Mar S.A. Compounds for use in the treatment of coronavirus infection
CN115594739B (zh) * 2021-06-28 2025-02-14 浙江珲达生物科技有限公司 一种dehydrodidemnin B类化合物的制备方法
WO2024165764A1 (en) 2023-02-10 2024-08-15 Pharma Mar, S.A. Plitidepsin for use in the treatment of non-integrated dna viral infections

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3161556D1 (en) 1980-09-12 1984-01-05 Univ Illinois Novel antibiotics, derivatives thereof, processes for their extraction, and compositions containing them
US4950649A (en) * 1980-09-12 1990-08-21 University Of Illinois Didemnins and nordidemnins
US4493796A (en) * 1980-09-12 1985-01-15 Board Of Trustees, Univ. Of Ill. Didemnins A, B, C, and derivatives thereof, as antiviral agents
IT1153974B (it) * 1982-09-23 1987-01-21 Erba Farmitalia Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento
US4948791A (en) * 1989-04-10 1990-08-14 The Board Of Trustees Of The University Of Illinois Novel Cytotoxic cyclic depsipeptides from the tunicate trididemnum solidum
GB8922026D0 (en) * 1989-09-29 1989-11-15 Pharma Mar Sa Novel anti-viral and cytotoxic agent
DE4120327A1 (de) * 1991-06-20 1992-12-24 Basf Ag Neue peptide, ihre herstellung und verwendung
US5462726A (en) * 1993-12-17 1995-10-31 Bristol-Myers Squibb Company Method of inhibiting side effects of solvents containing ricinoleic acid or castor oil or derivatives thereof employing a thromboxane A2 receptor antagonist and pharmaceutical compositions containing such solvents
US5861439A (en) * 1994-11-14 1999-01-19 Alza Corporation Method for enhanced electrotransport agent delivery
US6509316B2 (en) * 1995-03-07 2003-01-21 George Washington University Pharmaceutical compositions, methods, and kits for treatment and diagnosis of lung cancer
ES2102322B1 (es) 1995-07-13 1998-03-01 Pharma Mar Sa Procedimiento de preparacion de didemnina a.
EP0914116B1 (en) * 1996-05-22 2000-10-11 Protarga Inc. Compositions comprising conjugates of cis-docosahexaenoic acid and taxotere
US6156724A (en) * 1996-06-07 2000-12-05 Rinehart; Kenneth L. Uses of didemnins as immunomodulating agents
JP2001503746A (ja) * 1996-10-24 2001-03-21 ザ・ボード・オブ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・イリノイ ジデムニン類似体の半合成法
JP2001504814A (ja) * 1996-10-24 2001-04-10 ザ・ボード・オブ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・イリノイ ジデムニンAのアミノHip類似体の全合成
US6034058A (en) * 1997-04-15 2000-03-07 Rinehart; Kenneth L. Semi-synthetic alanyl dilemnin analogs
WO1998050048A1 (en) * 1997-05-07 1998-11-12 Pharma Mar, S.A. Aplidine as an l-type calcium channel enhancer
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
DE69923322T2 (de) 1998-07-30 2005-12-22 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Verwendung von propionyl-l-carnitin und acetyl-l-carnitin zur herstellung von arzneimittel mit antikrebs wirkung
US6890904B1 (en) * 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
HK1046846A1 (zh) 1999-05-25 2003-01-30 Point Therapeutics, Inc. 包含boroproline的抗肿瘤复合物
IL149488A0 (en) 1999-11-15 2002-11-10 Pharma Mar Sa Pharmaceutical compositions containing aplidine
ES2272462T3 (es) 2000-04-07 2007-05-01 The Trustees Of The University Of Pennsylvania Analogos de tamadarina y didemnina y procedimiento de fabricacion y uso.
US6509315B1 (en) * 2000-04-07 2003-01-21 The Trustees Of The University Of Pennsylvania Didemnin analogs and fragments and methods of making and using them
UA76718C2 (uk) * 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
WO2002030441A2 (en) 2000-10-12 2002-04-18 Pharma Mar, S.A. Treatment of cancers by aplidine in conjunction with a myoprotector
EP1435991B1 (en) 2001-10-19 2008-10-15 Pharma Mar, S.A. Use of aplidine for the treatment of pancreatic cancer
KR20060002778A (ko) 2003-03-12 2006-01-09 파르마 마르, 에스.에이. 개선된 항종양 치료

Also Published As

Publication number Publication date
HU228998B1 (en) 2013-07-29
HK1052940B (en) 2008-10-24
CA2414609C (en) 2012-04-24
HK1052940A1 (en) 2003-10-03
MXPA03000202A (es) 2003-10-15
EP1294747B1 (en) 2008-04-30
WO2002002596A2 (en) 2002-01-10
IL153680A0 (en) 2003-07-06
UA76718C2 (uk) 2006-09-15
SI1294747T1 (sl) 2008-12-31
JP5289662B2 (ja) 2013-09-11
HUP0301387A2 (hu) 2003-08-28
IL153680A (en) 2012-05-31
CN1449408A (zh) 2003-10-15
CA2414609A1 (en) 2002-01-10
CZ304204B6 (cs) 2014-01-02
NO20026242D0 (no) 2002-12-27
ATE393775T1 (de) 2008-05-15
KR100866056B1 (ko) 2008-10-30
BRPI0112375B8 (pt) 2021-05-25
BR0112375A (pt) 2003-06-24
NZ523367A (en) 2004-12-24
US7348310B2 (en) 2008-03-25
BRPI0112375B1 (pt) 2020-12-01
US20040097413A1 (en) 2004-05-20
NO20026242L (no) 2003-02-27
US20080009435A1 (en) 2008-01-10
DE60133817T2 (de) 2009-05-20
HUP0301387A3 (en) 2005-04-28
AU6769801A (en) 2002-01-14
WO2002002596A3 (en) 2002-05-23
ES2305083T3 (es) 2008-11-01
EP1294747A2 (en) 2003-03-26
PL208651B1 (pl) 2011-05-31
CN104650177A (zh) 2015-05-27
US7678765B2 (en) 2010-03-16
JP2004502702A (ja) 2004-01-29
NO334096B1 (no) 2013-12-09
PT1294747E (pt) 2008-08-08
CY1108549T1 (el) 2014-04-09
DE60133817D1 (de) 2008-06-12
KR20030013477A (ko) 2003-02-14
CZ20024233A3 (cs) 2003-06-18
DK1294747T3 (da) 2008-10-27

Similar Documents

Publication Publication Date Title
NZ523367A (en) Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them
SG149063A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
TW200510325A (en) 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
PH12013500123A1 (en) Hemiasterlin derivatives and uses thereof
IS2170B (is) Sýklópentanóindól, efnablöndur sem innihalda slíkefnasambönd og meðhöndlunaraðferðir
HRP20010738B1 (en) N-cyanomethyl amides as protease inhibitors
PL344475A1 (en) Bridged indenopyrrolocarbazoles
AU3831301A (en) Method for treating ocular pain
BG107220A (en) Antitumoral ecteinascudin derivatives
PL371127A1 (pl) Pochodne 6-amino-morfinianu, metody ich otrzymywania oraz ich zastosowania
AU5338401A (en) Methods and compositions for modulating alpha adrenergic receptor activity
IL163026A (en) Benzofuran and benzothiophene derivatives useful in the treatment of hyper-proliferative disorders
IL171974A0 (en) Tetrahydrocarbazole derivatives and their pharmaceutical use
WO2002010152A3 (de) Neue indolderivate und deren verwendung als arzneimittel
MXPA04000506A (es) Nuevos derivados de et-743 antitumorales.
MXPA04004090A (es) Compuestos substituidos de 1h-quinolin-2-ona.
MXPA05009428A (es) Composiciones y metodos para prevenir y tratar enfermedades relacionadas con endotoxinas.
EP1436279A4 (en) CHEMICAL COMPOUNDS
TW200505435A (en) Treatment of ocular disorders
MXPA03005400A (es) Metodo para preparacion de 11 (12)-pentadecen-15-olidos.
MXPA04004757A (es) Uso de una ascomicina para el tratamiento de blefaritis.
DE60120398D1 (de) Imidazopyridin-8-one
AU2002359762A1 (en) Luminacin analogs and uses thereof
UA49216A (uk) Засіб для лікування ускладнень після видалення злоякісних новоутворень шкіри
UA84701C2 (ru) Замещенные индолы, способ их получения, их использования

Legal Events

Date Code Title Description
RECP Rectifications of patent specification